Tonix Pharmaceuticals Stock Price, News & Analysis (NASDAQ:TNXP)

$3.82 0.04 (1.06 %)
(As of 12/11/2017 03:52 PM ET)
Previous Close$3.78
Today's Range$3.70 - $3.87
52-Week Range$2.85 - $9.40
Volume45,000 shs
Average Volume342,936 shs
Market Capitalization$29.91 million
P/E RatioN/A
Dividend YieldN/A
Beta2.92

About Tonix Pharmaceuticals (NASDAQ:TNXP)

Tonix Pharmaceuticals logoTonix Pharmaceuticals Holding Corp., a clinical-stage pharmaceutical company, engages in developing pharmaceutical products for central nervous system disorders. The company’s lead program focuses on post-traumatic stress disorder (PTSD) that is characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and economic burden. Its lead product candidate includes TNX-102 SL, a cyclobenzaprine HCl sublingual tablet, which is in Phase III clinical stage for the treatment of PTSD; and Phase III clinical stage for the treatment of military-related PTSD. The company’s product candidates also include TNX-601, an oral formulation of tianeptine oxalate for PTSD and cognitive dysfunction associated with steroid use; TNX-801, a smallpox-preventing vaccine based on a live synthetic version of horsepox virus; TNX-301, a fixed-dose combination drug product for alcohol use disorders; and TNX-701 for radiation injuries. Tonix Pharmaceuticals Holding Corp. was founded in 2007 and is based in New York, New York.

Receive TNXP News and Ratings via Email

Sign-up to receive the latest news and ratings for TNXP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:TNXP
CUSIPN/A
Phone212-980-9155

Debt

Debt-to-Equity RatioN/A
Current Ratio16.50%
Quick Ratio16.50%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$6.47 per share
Price / Book0.59

Profitability

Trailing EPS($4.77)
Net Income$-38,840,000.00
Net MarginsN/A
Return on Equity-78.25%
Return on Assets-73.14%

Miscellaneous

Employees18
Outstanding Shares7,830,000

Tonix Pharmaceuticals (NASDAQ:TNXP) Frequently Asked Questions

What is Tonix Pharmaceuticals' stock symbol?

Tonix Pharmaceuticals trades on the NASDAQ under the ticker symbol "TNXP."

How were Tonix Pharmaceuticals' earnings last quarter?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) posted its earnings results on Monday, August, 14th. The company reported ($0.65) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.78) by $0.13. View Tonix Pharmaceuticals' Earnings History.

When will Tonix Pharmaceuticals make its next earnings announcement?

Tonix Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, April, 16th 2018. View Earnings Estimates for Tonix Pharmaceuticals.

Where is Tonix Pharmaceuticals' stock going? Where will Tonix Pharmaceuticals' stock price be in 2017?

5 Wall Street analysts have issued 1 year price objectives for Tonix Pharmaceuticals' stock. Their forecasts range from $6.00 to $10.00. On average, they anticipate Tonix Pharmaceuticals' stock price to reach $8.33 in the next year. View Analyst Ratings for Tonix Pharmaceuticals.

Who are some of Tonix Pharmaceuticals' key competitors?

Who owns Tonix Pharmaceuticals stock?

Tonix Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include B. Riley Financial Inc. (3.60%) and Susquehanna International Group LLP (0.58%). Company insiders that own Tonix Pharmaceuticals stock include Bradley Saenger, Bruce Daugherty, Ernest Mario, Gregory M Sullivan, John B Rhodes and Seth Lederman. View Institutional Ownership Trends for Tonix Pharmaceuticals.

Who sold Tonix Pharmaceuticals stock? Who is selling Tonix Pharmaceuticals stock?

Tonix Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including B. Riley Financial Inc. and Susquehanna International Group LLP. View Insider Buying and Selling for Tonix Pharmaceuticals.

How do I buy Tonix Pharmaceuticals stock?

Shares of Tonix Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Tonix Pharmaceuticals' stock price today?

One share of Tonix Pharmaceuticals stock can currently be purchased for approximately $3.82.

How big of a company is Tonix Pharmaceuticals?

Tonix Pharmaceuticals has a market capitalization of $29.91 million. The company earns $-38,840,000.00 in net income (profit) each year or ($4.77) on an earnings per share basis. Tonix Pharmaceuticals employs 18 workers across the globe.

How can I contact Tonix Pharmaceuticals?

Tonix Pharmaceuticals' mailing address is 509 MADISON AVE. - SUITE 306, NEW YORK NY, 10022. The company can be reached via phone at 212-980-9155 or via email at [email protected]


MarketBeat Community Rating for Tonix Pharmaceuticals (TNXP)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  129 (Vote Outperform)
Underperform Votes:  64 (Vote Underperform)
Total Votes:  193
MarketBeat's community ratings are surveys of what our community members think about Tonix Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Tonix Pharmaceuticals (NASDAQ:TNXP) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyHold
Consensus Rating Score: 2.672.672.672.00
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $7.50$8.60$8.60$8.67
Price Target Upside: 95.31% upside167.91% upside167.91% upside1,620.94% upside

Tonix Pharmaceuticals (NASDAQ:TNXP) Consensus Price Target History

Price Target History for Tonix Pharmaceuticals (NASDAQ:TNXP)

Tonix Pharmaceuticals (NASDAQ:TNXP) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/1/2017AegisReiterated RatingBuyMediumView Rating Details
8/23/2017Dawson JamesReiterated RatingBuy$9.00MediumView Rating Details
8/22/2017Drexel HamiltonInitiated CoverageBuyHighView Rating Details
8/18/2017Roth CapitalUpgradeNeutral -> Buy$6.00HighView Rating Details
12/20/2016OppenheimerReiterated RatingHoldN/AView Rating Details
9/7/2016Cantor FitzgeraldDowngradeBuy -> HoldN/AView Rating Details
(Data available from 12/11/2015 forward)

Earnings

Tonix Pharmaceuticals (NASDAQ:TNXP) Earnings History and Estimates Chart

Earnings by Quarter for Tonix Pharmaceuticals (NASDAQ:TNXP)

Tonix Pharmaceuticals (NASDAQ TNXP) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/16/2018        
8/14/2017Q2 2017($0.78)($0.65)ViewN/AView Earnings Details
5/15/2017Q1 2017($1.36)($1.27)ViewN/AView Earnings Details
11/10/2016Q3 2016($0.34)($0.29)ViewN/AView Earnings Details
5/9/2016Q1($0.63)($0.74)ViewN/AView Earnings Details
3/4/2016Q4($0.66)($0.71)ViewN/AView Earnings Details
8/10/2015Q215($0.65)($0.73)ViewN/AView Earnings Details
5/11/2015Q115($0.54)($0.71)ViewN/AView Earnings Details
3/3/2015Q414($0.81)($0.83)ViewN/AView Earnings Details
11/10/2014Q314($0.69)($0.71)ViewN/AView Earnings Details
8/8/2014Q214($0.53)($0.61)ViewN/AView Earnings Details
5/13/2014Q114($0.35)($0.59)ViewN/AView Earnings Details
3/31/2014($0.46)($0.74)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Tonix Pharmaceuticals (NASDAQ:TNXP) Earnings Estimates

2017 EPS Consensus Estimate: ($2.79)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.83)($0.83)($0.83)
Q2 20171($0.69)($0.69)($0.69)
Q3 20171($0.65)($0.65)($0.65)
Q4 20171($0.62)($0.62)($0.62)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Tonix Pharmaceuticals (NASDAQ:TNXP)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Tonix Pharmaceuticals (NASDAQ TNXP) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.00%
Institutional Ownership Percentage: 17.51%
Insider Trades by Quarter for Tonix Pharmaceuticals (NASDAQ:TNXP)
Insider Trades by Quarter for Tonix Pharmaceuticals (NASDAQ:TNXP)

Tonix Pharmaceuticals (NASDAQ TNXP) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/17/2017Seth LedermanCEOBuy20,000$3.00$60,000.00View SEC Filing  
6/30/2017Ernest MarioDirectorSell6,105$4.28$26,129.40View SEC Filing  
6/30/2017Seth LedermanCEOBuy5,000$4.33$21,650.00View SEC Filing  
6/26/2017Seth LedermanCEOBuy5,000$4.40$22,000.00View SEC Filing  
6/20/2017Seth LedermanCEOBuy20,000$4.22$84,400.00View SEC Filing  
11/23/2016Ernest MarioDirectorBuy120,000$0.41$49,200.00View SEC Filing  
9/13/2016Ernest MarioDirectorBuy100,000$0.79$79,000.00View SEC Filing  
6/22/2016Seth LedermanCEOBuy20,000$2.08$41,600.00View SEC Filing  
6/21/2016Bradley SaengerCFOBuy2,000$2.00$4,000.00View SEC Filing  
6/21/2016Bruce DaughertyInsiderBuy100,000$2.00$200,000.00View SEC Filing  
6/21/2016John B RhodesDirectorBuy25,000$2.00$50,000.00View SEC Filing  
6/3/2016Gregory M SullivanInsiderBuy20,000$2.50$50,000.00View SEC Filing  
5/12/2016Ernest MarioDirectorBuy31,042$2.30$71,396.60View SEC Filing  
5/11/2016Ernest MarioDirectorBuy8,210$2.24$18,390.40View SEC Filing  
3/23/2016Seth LedermanCEOBuy8,000$2.44$19,520.00View SEC Filing  
3/16/2016Ernest MarioDirectorBuy75,000$2.29$171,750.00View SEC Filing  
9/30/2015Gregory M SullivanInsiderBuy5,000$5.18$25,900.00View SEC Filing  
9/28/2015Gregory M SullivanInsiderBuy4,694$5.95$27,929.30View SEC Filing  
9/25/2015Seth LedermanCEOBuy6,000$6.50$39,000.00View SEC Filing  
8/26/2015Ernest MarioDirectorBuy10,000$6.05$60,500.00View SEC Filing  
8/25/2015Ernest MarioDirectorBuy1,468$6.40$9,395.20View SEC Filing  
8/24/2015Ernest MarioDirectorBuy2,532$6.20$15,698.40View SEC Filing  
8/20/2015Ernest MarioDirectorBuy6,000$6.64$39,840.00View SEC Filing  
8/17/2015Ernest MarioDirectorBuy15,000$6.93$103,950.00View SEC Filing  
7/17/2015John B RhodesDirectorBuy6,000$7.50$45,000.00View SEC Filing  
7/17/2015Leland GershellCFOBuy1,000$7.50$7,500.00View SEC Filing  
6/11/2015Gregory M SullivanInsiderBuy4,500$8.38$37,710.00View SEC Filing  
3/17/2015Seth LedermanCEOBuy2,000$7.02$14,040.00View SEC Filing  
3/13/2015Seth LedermanCEOBuy2,000$7.24$14,480.00View SEC Filing  
3/11/2015Seth LedermanCEOBuy2,000$6.95$13,900.00View SEC Filing  
3/10/2015Charles E Iv MatherDirectorBuy1,000$6.80$6,800.00View SEC Filing  
3/9/2015Seth LedermanCEOBuy2,000$6.48$12,960.00View SEC Filing  
3/6/2015Ernest MarioDirectorBuy4,000$6.57$26,280.00View SEC Filing  
3/5/2015Seth LedermanCEOBuy2,000$6.27$12,540.00View SEC Filing  
2/9/2015Ernest MarioDirectorBuy30,000$5.85$175,500.00View SEC Filing  
2/9/2015Leland GershellCFOBuy5,000$5.85$29,250.00View SEC Filing  
9/27/2013Charles E Iv MatherDirectorBuy1,000$3.65$3,650.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Tonix Pharmaceuticals (NASDAQ TNXP) News Headlines

Source:
DateHeadline
Head-To-Head Survey: Tonix Pharmaceuticals (TNXP) & Innovus Pharmaceuticals (INNV)Head-To-Head Survey: Tonix Pharmaceuticals (TNXP) & Innovus Pharmaceuticals (INNV)
www.americanbankingnews.com - December 10 at 9:08 PM
Head to Head Review: Echo Therapeutics (ECTE) & Tonix Pharmaceuticals (TNXP)Head to Head Review: Echo Therapeutics (ECTE) & Tonix Pharmaceuticals (TNXP)
www.americanbankingnews.com - December 9 at 11:42 PM
Tonix Pharmaceuticals (TNXP) Buy Rating Reaffirmed at AegisTonix Pharmaceuticals' (TNXP) Buy Rating Reaffirmed at Aegis
www.americanbankingnews.com - December 7 at 7:00 PM
Tonix Pharmaceuticals (TNXP) Rating Lowered to Strong Sell at ValuEngineTonix Pharmaceuticals (TNXP) Rating Lowered to Strong Sell at ValuEngine
www.americanbankingnews.com - December 2 at 10:26 AM
Reviewing Innovus Pharmaceuticals (INNV) and Tonix Pharmaceuticals (TNXP)Reviewing Innovus Pharmaceuticals (INNV) and Tonix Pharmaceuticals (TNXP)
www.americanbankingnews.com - December 2 at 1:30 AM
Tonix Pharmaceuticals Holding Corp. (TNXP) Receives Average Rating of "Buy" from AnalystsTonix Pharmaceuticals Holding Corp. (TNXP) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - December 1 at 3:54 PM
Tonix Pharmaceuticals to Present at 10th Annual LD Micro Investor ... - GlobeNewswire (press release)Tonix Pharmaceuticals to Present at 10th Annual LD Micro Investor ... - GlobeNewswire (press release)
globenewswire.com - November 30 at 3:32 PM
Tonix Pharmaceuticals to Present at 10th Annual LD Micro Investor ConferenceTonix Pharmaceuticals to Present at 10th Annual LD Micro Investor Conference
feeds.benzinga.com - November 30 at 7:52 AM
Tonix Pharmaceuticals (TNXP) versus Innovus Pharmaceuticals (INNV) Head-To-Head ReviewTonix Pharmaceuticals (TNXP) versus Innovus Pharmaceuticals (INNV) Head-To-Head Review
www.americanbankingnews.com - November 28 at 3:34 PM
 Analysts Expect Tonix Pharmaceuticals Holding Corp. (TNXP) Will Announce Earnings of -$0.72 Per Share Analysts Expect Tonix Pharmaceuticals Holding Corp. (TNXP) Will Announce Earnings of -$0.72 Per Share
www.americanbankingnews.com - November 28 at 3:27 AM
Echo Therapeutics (ECTE) vs. Tonix Pharmaceuticals (TNXP) Head-To-Head ContrastEcho Therapeutics (ECTE) vs. Tonix Pharmaceuticals (TNXP) Head-To-Head Contrast
www.americanbankingnews.com - November 27 at 10:26 AM
Contrasting Echo Therapeutics (ECTE) and Tonix Pharmaceuticals Holding Corp. (TNXP)Contrasting Echo Therapeutics (ECTE) and Tonix Pharmaceuticals Holding Corp. (TNXP)
www.americanbankingnews.com - November 18 at 5:42 AM
Head to Head Survey: Echo Therapeutics (ECTE) and Tonix Pharmaceuticals Holding Corp. (TNXP)Head to Head Survey: Echo Therapeutics (ECTE) and Tonix Pharmaceuticals Holding Corp. (TNXP)
www.americanbankingnews.com - November 15 at 5:27 PM
Tonix Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Programs UpdateTonix Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Programs Update
finance.yahoo.com - November 7 at 12:15 PM
Tonix reports 3Q lossTonix reports 3Q loss
finance.yahoo.com - November 7 at 12:15 PM
Tonix Pharmaceuticals Holding Corp. (TNXP) Receives Consensus Recommendation of "Buy" from AnalystsTonix Pharmaceuticals Holding Corp. (TNXP) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - November 6 at 10:35 AM
Tonix Pharmaceuticals to Present at 23rd Annual BIO-Europe International Partnering ConferenceTonix Pharmaceuticals to Present at 23rd Annual BIO-Europe International Partnering Conference
finance.yahoo.com - November 1 at 9:44 AM
Tonix Pharmaceuticals Holding Corp. (TNXP) to Release Quarterly Earnings on WednesdayTonix Pharmaceuticals Holding Corp. (TNXP) to Release Quarterly Earnings on Wednesday
www.americanbankingnews.com - November 1 at 4:50 AM
Tonix Pharmaceuticals (TNXP) Presents At 3rd Annual Dawson James Small Cap Growth Conference 2017 - SlideshowTonix Pharmaceuticals (TNXP) Presents At 3rd Annual Dawson James Small Cap Growth Conference 2017 - Slideshow
seekingalpha.com - October 21 at 9:23 AM
-$0.68 Earnings Per Share Expected for Tonix Pharmaceuticals Holding Corp. (TNXP) This Quarter-$0.68 Earnings Per Share Expected for Tonix Pharmaceuticals Holding Corp. (TNXP) This Quarter
www.americanbankingnews.com - October 20 at 6:24 PM
BRIEF-Tonix Pharma reports outcomes from CMC guidance meeting with FDA on TonmyaBRIEF-Tonix Pharma reports outcomes from CMC guidance meeting with FDA on Tonmya
www.reuters.com - October 19 at 9:55 AM
Tonix Pharma (TNXP) Says in General Its Proposed CMC Data Package to Support Tonmyas NDA and Commercial ... - StreetInsider.comTonix Pharma (TNXP) Says in General Its Proposed CMC Data Package to Support Tonmya's NDA and Commercial ... - StreetInsider.com
www.streetinsider.com - October 18 at 9:40 AM
Tonix Pharmaceuticals Reports Outcomes from U.S. FDA Breakthrough Therapy CMC Guidance Meeting of Tonmya® (Cyclobenzaprine HCI Sublingual Tablets) for PTSDTonix Pharmaceuticals Reports Outcomes from U.S. FDA Breakthrough Therapy CMC Guidance Meeting of Tonmya® (Cyclobenzaprine HCI Sublingual Tablets) for PTSD
finance.yahoo.com - October 17 at 8:11 AM
Tonix Pharmaceuticals to Present at the Dawson James Securities 3rd Annual Small Cap Growth ConferenceTonix Pharmaceuticals to Present at the Dawson James Securities 3rd Annual Small Cap Growth Conference
finance.yahoo.com - October 13 at 9:21 AM
Tonix Pharmaceuticals Holding Corp. (TNXP) Receives Average Recommendation of "Buy" from BrokeragesTonix Pharmaceuticals Holding Corp. (TNXP) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - October 12 at 1:18 PM
Tonix Pharmaceuticals Holding Corp’s (TNXP): From Cash To Ash?Tonix Pharmaceuticals Holding Corp’s (TNXP): From Cash To Ash?
finance.yahoo.com - October 6 at 11:32 AM
Tonix Pharmaceuticals Presented at the 2nd Annual Cohen Veterans Care Summit in Washington, D.C.Tonix Pharmaceuticals Presented at the 2nd Annual Cohen Veterans Care Summit in Washington, D.C.
feeds.benzinga.com - September 29 at 8:21 AM
Tonix Pharmaceuticals Holding Corp. (TNXP) Receives Average Recommendation of "Buy" from AnalystsTonix Pharmaceuticals Holding Corp. (TNXP) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - September 17 at 10:58 AM
Tonix Pharmaceuticals (TNXP) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - SlideshowTonix Pharmaceuticals (TNXP) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow
seekingalpha.com - September 15 at 10:04 AM
Tonix Pharmaceuticals Elects Margaret Smith Bell to the Board of Directors - GlobeNewswire (press release)Tonix Pharmaceuticals Elects Margaret Smith Bell to the Board of Directors - GlobeNewswire (press release)
globenewswire.com - September 14 at 11:26 AM
Tonix Pharma (TNXP) Appoints Margaret Bell to Board - StreetInsider.comTonix Pharma (TNXP) Appoints Margaret Bell to Board - StreetInsider.com
www.streetinsider.com - September 14 at 11:26 AM
Tonix Pharmaceuticals Elects Margaret Smith Bell to the Board of DirectorsTonix Pharmaceuticals Elects Margaret Smith Bell to the Board of Directors
finance.yahoo.com - September 14 at 11:26 AM
 Brokerages Anticipate Tonix Pharmaceuticals Holding Corp. (TNXP) Will Post Earnings of -$0.68 Per Share Brokerages Anticipate Tonix Pharmaceuticals Holding Corp. (TNXP) Will Post Earnings of -$0.68 Per Share
www.americanbankingnews.com - September 13 at 4:24 AM
Tonix Pharmaceuticals Holding Corp. (TNXP) vs. Innovus Pharmaceuticals (INNV) Head-To-Head ComparisonTonix Pharmaceuticals Holding Corp. (TNXP) vs. Innovus Pharmaceuticals (INNV) Head-To-Head Comparison
www.americanbankingnews.com - September 11 at 10:06 PM
Corporate News Blog - Eli Lillys Galcanezumab Treatment Shows Positive Safety Results in the 12-Month Phase-3 StudyCorporate News Blog - Eli Lilly's Galcanezumab Treatment Shows Positive Safety Results in the 12-Month Phase-3 Study
finance.yahoo.com - September 11 at 7:49 AM
Critical Review: Tonix Pharmaceuticals Holding Corp. (TNXP) vs. Innovus Pharmaceuticals (INNV)Critical Review: Tonix Pharmaceuticals Holding Corp. (TNXP) vs. Innovus Pharmaceuticals (INNV)
www.americanbankingnews.com - September 11 at 6:20 AM
Contrasting Tonix Pharmaceuticals Holding Corp. (TNXP) & Innovus Pharmaceuticals (INNV)Contrasting Tonix Pharmaceuticals Holding Corp. (TNXP) & Innovus Pharmaceuticals (INNV)
www.americanbankingnews.com - September 9 at 8:12 PM
Tonix Pharmaceuticals Holding Corp. (TNXP) & Innovus Pharmaceuticals (INNV) Critical AnalysisTonix Pharmaceuticals Holding Corp. (TNXP) & Innovus Pharmaceuticals (INNV) Critical Analysis
www.americanbankingnews.com - September 9 at 11:06 AM
Tonix Pharmaceuticals to Present at the Rodman & Renshaw 19th Annual Global Investment Conference - GlobeNewswire (press release)Tonix Pharmaceuticals to Present at the Rodman & Renshaw 19th Annual Global Investment Conference - GlobeNewswire (press release)
globenewswire.com - September 6 at 9:15 AM
Tonix Pharmaceuticals to Present at the Rodman & Renshaw 19th Annual Global Investment ConferenceTonix Pharmaceuticals to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
finance.yahoo.com - September 6 at 9:15 AM
Head to Head Contrast: Innovus Pharmaceuticals (INNV) & Tonix Pharmaceuticals Holding Corp. (TNXP)Head to Head Contrast: Innovus Pharmaceuticals (INNV) & Tonix Pharmaceuticals Holding Corp. (TNXP)
www.americanbankingnews.com - September 5 at 6:16 AM
Comparing Innovus Pharmaceuticals (INNV) & Tonix Pharmaceuticals Holding Corp. (TNXP)Comparing Innovus Pharmaceuticals (INNV) & Tonix Pharmaceuticals Holding Corp. (TNXP)
www.americanbankingnews.com - September 4 at 12:34 PM
Head to Head Contrast: Innovus Pharmaceuticals (INNV) vs. Tonix Pharmaceuticals Holding Corp. (TNXP)Head to Head Contrast: Innovus Pharmaceuticals (INNV) vs. Tonix Pharmaceuticals Holding Corp. (TNXP)
www.americanbankingnews.com - September 3 at 4:26 PM
Financial Survey: Tonix Pharmaceuticals Holding Corp. (TNXP) vs. Innovus Pharmaceuticals (INNV)Financial Survey: Tonix Pharmaceuticals Holding Corp. (TNXP) vs. Innovus Pharmaceuticals (INNV)
www.americanbankingnews.com - August 31 at 10:31 PM
Tonix Pharma (TNXP) Released Additional Phase 2 Clinical Results in Military-Related PTSD and Design of Ongoing ... - StreetInsider.comTonix Pharma (TNXP) Released Additional Phase 2 Clinical Results in Military-Related PTSD and Design of Ongoing ... - StreetInsider.com
www.streetinsider.com - August 30 at 10:21 AM
Tonix Pharma (TNXP) Released Additional Phase 2 Clinical Results in Military-Related PTSD and Design of Ongoing ... - StreetInsider.comTonix Pharma (TNXP) Released Additional Phase 2 Clinical Results in Military-Related PTSD and Design of Ongoing ... - StreetInsider.com
www.streetinsider.com - August 30 at 10:21 AM
Tonix Pharmaceuticals Presented Additional Phase 2 Clinical Results in Military-Related PTSD and Design of Ongoing Phase 3 Trial at the 2017 Military Health System Research SymposiumTonix Pharmaceuticals Presented Additional Phase 2 Clinical Results in Military-Related PTSD and Design of Ongoing Phase 3 Trial at the 2017 Military Health System Research Symposium
finance.yahoo.com - August 30 at 10:21 AM
Tonix Pharmaceuticals Presented Additional Phase 2 Clinical Results in Military-Related PTSD and Design of Ongoing Phase 3 Trial at the 2017 Military Health System Research SymposiumTonix Pharmaceuticals Presented Additional Phase 2 Clinical Results in Military-Related PTSD and Design of Ongoing Phase 3 Trial at the 2017 Military Health System Research Symposium
finance.yahoo.com - August 30 at 10:21 AM
Critical Comparison: Tonix Pharmaceuticals Holding Corp. (TNXP) versus Innovus Pharmaceuticals (INNV)Critical Comparison: Tonix Pharmaceuticals Holding Corp. (TNXP) versus Innovus Pharmaceuticals (INNV)
www.americanbankingnews.com - August 26 at 12:22 AM
 Analysts Anticipate Tonix Pharmaceuticals Holding Corp. (TNXP) to Announce -$0.68 EPS Analysts Anticipate Tonix Pharmaceuticals Holding Corp. (TNXP) to Announce -$0.68 EPS
www.americanbankingnews.com - August 25 at 8:18 PM

SEC Filings

Tonix Pharmaceuticals (NASDAQ:TNXP) SEC Filings

DateFilerForm TypeView

Social Media

Financials

Tonix Pharmaceuticals (NASDAQ:TNXP) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Tonix Pharmaceuticals (NASDAQ TNXP) Stock Chart for Monday, December, 11, 2017

Loading chart…

This page was last updated on 12/11/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.